PRE

$19.62-1.53 (-7.23%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Prenetics Global Limited, a health sciences company, focuses on advancing consumer health in Hong Kong, the United States, and internationally.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$19.62
Potential Upside
5%
Whystock Fair Value$20.60
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

Prenetics Global Limited, a health sciences company, focuses on advancing consumer health in Hong Kong, the United States, and internationally. It sells health and wellness products under the IM8 brand name; and provides fulfillment and distribution ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$330.17M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-172.24%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.51

Recent News

MarketBeat
Mar 21, 2026

Prenetics Global CEO Touts IM8 Breakout Growth, Guides $180M-$200M Revenue at Conference

Prenetics Global (NASDAQ:PRE) CEO and co-founder Danny Yeung told investors the company delivered what he described as a “breakout growth story” in 2025, driven by the rapid expansion of its IM8 direct-to-consumer supplements business and a broader strategic shift to focus on that brand. 2025 perfo

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 4, 2026

Prenetics Global (PRE) Reports 480% Revenue Surge Driven by IM8 Brand Launch

Prenetics Global Limited (NASDAQ:PRE) is one of the most promising micro-cap stocks according to analysts. On February 18, Prenetics Global Limited reported financial results for 2025, headlined by a 480% year-over-year revenue surge to $92.4 million. This was fueled by the company’s flagship health and longevity brand, IM8, which reached an ARR of $120 million […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Feb 19, 2026

Prenetics Global Limited Q4 2025 Earnings Call Summary

Moby summary of Prenetics Global Limited's Q4 2025 earnings call

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MT Newswires
Feb 18, 2026

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index decreasing 0

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 18, 2026

Prenetics Global Q4 Earnings Call Highlights

Prenetics Global (NASDAQ:PRE) used its fourth-quarter and full-year 2025 earnings call to detail what Chief Executive Officer and Co-founder Danny Yeung described as a “transformative” year, driven primarily by the launch of its premium consumer health brand IM8, which was co-founded with David Beck

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.